Erythropoietin (EPO) regulation of red blood cell production and its induction at reduced
oxygen tension provides for the important erythropoietic response to ischemic stress. The …

Erythropoietin (Epo) has been thought to act exclusively on erythroid progenitor cells. The
identification of Epo receptor (EpoR) in non-haematopoietic cells and tissues including …

Following the original large-scale randomized trials of aspirin and β-blockade, there have
been a number of major advances in pharmacological and mechanical treatments for acute …

Ischaemia (interruption in the blood/oxygen supply) and subsequent damage induced by
reperfusion (restoration of blood/oxygen supply) ultimately leads to cell death, tissue injury …

Background Erythropoietin (EPO) has been suggested to promote cardiac repair after MI.
However, the randomized, double-blind, placebo controlled REVIVAL-3 trial showed that …

Neuroprotective drugs to protect the brain against cerebral ischemia and reperfusion (I/R)
injury are urgently needed. Mammalian cell-produced recombinant human erythropoietin …

Ischaemia–reperfusion injury (IRI) during various surgical procedures, including partial
nephrectomy for kidney cancer or renal transplantation, is a major cause of acute kidney …

Erythropoietin (EPO) is the main hormone that regulates erythropoiesis. Beyond its well-
known hematopoietic action, EPO has diverse cellular effects in non-hematopoietic tissues …

Discovered as the primary regulator of erythropoiesis, erythropoietin (EPO) is involved in a
broad variety of processes that play a major role in cardiovascular diseases. In particular …

We developed a novel adenylyl cyclase type 5 (AC5) inhibitor, C90, that reduces myocardial
infarct size even when administered after coronary reperfusion. This is key, since it is not …